Phase IIa Trial in Participants With Asthma to Evaluate Impact of Intranasal ETH47 on Development of Asthma-related Symptoms Following Rhinovirus Challenge

This study is testing a nasal spray called ETH47 in people with asthma to see whether it can reduce asthma symptoms when participants are deliberately exposed to a common cold virus (rhinovirus) in a controlled clinical setting. Rhinovirus infections are a leading trigger of asthma attacks. **You may be eligible if...** - You are between 18 and 65 years of age - You have a confirmed diagnosis of asthma (demonstrated by standard breathing tests) - Your asthma is mild to moderate and reasonably controlled - You have a positive blood test showing prior rhinovirus immunity (or specific eligibility for the virus challenge) - You are a non-smoker or have very limited smoking history **You may NOT be eligible if...** - You have severe or poorly controlled asthma - You have significant heart, immune, or other serious health conditions - You are pregnant or breastfeeding - You have had a respiratory infection in the past 6 weeks - You are currently on oral steroids or immunotherapy Talk to your doctor to see if this trial is right for you.